Drug Search Results
More Filters [+]

Foscarnet

Alternative Names: foscarnet, foscavir
Latest Update: 2024-11-13
Latest Update Note: Clinical Trial Update

Product Description

Foscarnet is a medication used to manage and treat CMV, HSV, and VZV viral infections in AIDS and immunocompromised patients. It is in the antiviral class of drugs. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK556108/)

Mechanisms of Action: DNA Polymerase Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Canada | Chile | China | Colombia | Czech | Denmark | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Ireland | Israel | Italy | Japan | Korea | Latvia | Lithuania | Luxembourg | Malta | Netherlands | New Zealand | Peru | Poland | Portugal | Saudi Arabia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Turkey | United Kingdom | United States | Uruguay

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Foscarnet

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events